![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » DYNAVAX ESTABLISHES COLLABORATION FOR TLR-9 AGONISTS FOR ASTHMA AND COPD WITH ASTRAZENECA
DYNAVAX ESTABLISHES COLLABORATION FOR TLR-9 AGONISTS FOR ASTHMA AND COPD WITH ASTRAZENECA
Dynavax Technologies Corporation has entered into a research collaboration and license agreement with AstraZeneca for the discovery and development of TLR-9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The collaboration will utilize Dynavax's proprietary second-generation TLR-9 agonist immunostimulatory sequences or ISS. Drug Newswire (http://www.drugnewswire.com/5588/)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct